The private equity firm, Celtic Therapeutics Holdings LP, has announced plans to invest up to $15 million in the clinical investigation of a cancer drug developed by the privately-owned UK company, Spirogen Ltd.
A two-year old Swedish company with a novel strategy for treating cancer, Axcentua Pharmaceuticals AB, has raised an undisclosed amount of money in a Series A financing round. It will use the funds to bring its lead molecule into the clinic.
Sir Greg Winter, a founder of both Cambridge Antibody Technology and Domantis, has put his scientific and entrepreneurial skills to work again as the scientific co-founder of new company in the UK that is developing mini-antibodies.
UCB SA, which develops and sells treatments for diseases of the central nervous system and the immune system, has successfully floated a €500 million convertible eurobond issue.
Santhera Pharmaceuticals Holding AG of Switzerland has completed an all-share acquisition of Oy Juvantia Pharma Ltd of Finland thereby giving it control of a compound for the treatment of dyskinesia in Parkinson’s disease.
Antisoma Plc said it is gearing up towards the regulatory filing and eventual commercialisation of its most advanced cancer product. Meanwhile, the UK company said its cash resources should fund all of its priority programmes until mid-2011.
Ablynx NV is set to receive payments totalling €5.72 million from Wyeth Pharmaceuticals and Boehringer Ingelheim following the achievement of milestones in separate collaborations with the two companies
The Riverside Company, a private equity group with offices in Brussels, Belgium, has acquired Crioestaminal SA of Portugal which collects stem cells from umbilical cord blood.
Pronova BioPharma ASA of Norway has doubled the production capacity for omega-3-acid ethyl esters, the active pharmaceutical ingredient of Omacor, its prescription medicine for heart disease, with the opening of a new plant in Denmark.
Sanofi-aventis said it has reached an agreement to buy the privately-owned French opthalmology company, Fovea Pharmaceuticals SA, for up to €370 million. This includes €90 million upfront as well as future milestone payments.